|
| Research on the mechanism of network pharmacology of Maxing Shigan Decoction for “treating different diseases with the same treatment” in mycoplasma pneumoniae pneumonia and bronchial asthma |
| Hits 544 Download times 395 Received:May 13, 2023 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2023.07.17 |
| Key Words
mycoplasma pneumoniae pneumonia;bronchial asthma;Maxing Shigan Decoction;different diseases with the same treatment;network pharmacology |
| Author Name | Affiliation | E-mail | | WU Xiaoxia | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300193, China | | | LI Huanmin | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300193, China | | | SUN Dan | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300193, China | | | HAN Yaowei | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300193, China | | | LI Xinmin | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300193, China | tjtcmlxm@163.com。 |
|
| Abstract
|
| [Objective] In this study，network pharmacology and molecular docking techniques will be used to explore the common potential target and mechanism of Maxing Shigan Decoction for “treating different diseases with the same treatment” in mycoplasma pneumoniae pneumonia （MPP） and bronchial asthma （BA）. [Methods] The active ingredients and their targets of Maxing Shigan Decoction were screened by searching the traditional Chinese medicine systems pharmacology database and analysis platform（TCMSP） and the Chinese knowledge resource database（CNKI），and standardized by UniProt database. Related disease targets of MPP and BA were obtained respectively by using databases of GeneCards，OMIM. Venny 2.1 was used to obtain drug-disease common target. A disease-drug-component-target network was constructed by using Cytoscape 3.9.1 .The intersection targets were input into STRING database for protein-protein interaction PPI network construction. GO enrichment analysis and KEGG pathway enrichment analysis of common targets were performed using the DAVID database. Finally，AutoDockTools software was used to connect the core components with key targets. [Results] Totally 123 active components of Maxing Shigan Decoction and 208 related targets were screened. There were 374 MPP disease targets，2 623 BA disease targets，and 46 drug-disease intersection targets were obtained. GO functional enrichment analysis obtained 276 biological processes （P<0.05），15 cellular compositions （P<0.05），and 33 molecular functions （P<0.05）. KEGG pathway enrichment analysis showed that the common pathways of Maxing Shigan Decoction in the treatment of MPP and BA were mainly AGE-RAGE signaling pathway，IL-17 signaling pathway，TNF signaling pathway，and HIF-1 signaling pathway for diabetic complications. Molecular docking showed that the core components could mostly form stable structures with the key target. [Conclusion] Maxing Shigan Decoction treats MPP and BA through the characteristics of multiple components，multiple targets and multiple ways，providing new ideas for the theory of “treating different diseases with the same treatment” in TCM，and also providing a bioinformatics basis for the clinical application and mechanism study of Maxing Shigan Decoction. |
|
|
|
|
|
|
|
